Key result
RF RDN linked to durable BP reductions and ~18% lower all-cause mortality versus conservative management.
Why the study?
Although renal denervation has been approved in guidelines for resistant or uncontrolled hypertension, its long-term outcomes required evaluation.
Does radiofrequency renal denervation provide durable long-term blood pressure reduction in patients with uncontrolled hypertension?
Cohort (n=141)
No
Does radiofrequency renal denervation provide durable long-term blood pressure reduction in patients with uncontrolled hypertension?
Absolute Event Rate: 9.3% vs 11.4%
Radiofrequency renal denervation provides durable, significant reductions in both office and ambulatory blood pressure over a mean follow-up of 8 years in patients with uncontrolled hypertension.
RDN was associated with durable BP reductions over 8 years without excess mortality; extends observational data but leaves causal effects open.
Objective: Renal denervation (RDN) has been approved in recent guidelines as the third pillar for the management of resistant or uncontrolled hypertension. The aim of this study was to evaluate the long-term outcomes of radiofrequency (RF) RDN in a cohort of patients treated at an ESH center of excellence, with a mean follow-up of 8 years. Design and method: From a pool of patients with uncontrolled hypertension who had previously undergone RF RDN, we included those with a follow-up longer than 3 years (n=97). Baseline and follow-up data were collected for each patient, including office blood pressure (OBP), ambulatory blood pressure (ABP), use of antihypertensive medication, and markers of renal function. A propensity-matched control group of patients with resistant hypertension managed conservatively (without RDN) was selected for comparison. All-cause mortality and non-fatal cardiovascular events were recorded. Results: A total of 76 patients (mean age 61.4±10.5 years, 25% female) had follow-up data over a mean of 8.3±3.4 years. OBP decreased significantly from baseline by 21.8±16.9 mmHg systolic and 13.1±9.6 mmHg diastolic (p<0.001 for both). In 41 patients with ABP data, systolic ABP decreased by 19.4±13.1 mmHg and diastolic ABP by 12.7±10.0 mmHg (p<0.001 for both). The number of prescribed antihypertensive medications was reduced by 0.54±1.2 (p<0.01). By the end of follow-up, 9 of the 97 RDN patients (9.3%) had died, compared with 5 of 44 control patients (11.4%) over a mean follow-up of 8.1±2.3 years. Twelve patients were lost to follow-up. Estimated glomerular filtration rate declined significantly in the RDN group from 83.0±14.4 to 75.5±19.2 mL/min/1.73 m2 (p<0.001).Conclusions: RDN is a safe procedure that provides durable antihypertensive effects lasting for at least 8 years.
No takes yet. Share an insight, caveat, or question.
Kyriakoulis et al. (2026) conducted a cohort in Resistant or uncontrolled hypertension (n=141). Radiofrequency renal denervation vs. Conservative management (without renal denervation) was evaluated on All-cause mortality. Radiofrequency renal denervation provided durable blood pressure reductions over 8 years, with all-cause mortality occurring in 9.3% of RDN patients versus 11.4% of conservatively managed controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: